GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NxStage Medical Inc (NAS:NXTM) » Definitions » Net Income

NxStage Medical (NxStage Medical) Net Income : $-5.4 Mil (TTM As of Sep. 2018)


View and export this data going back to 2005. Start your Free Trial

What is NxStage Medical Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. NxStage Medical's Net Income for the three months ended in Sep. 2018 was $0.9 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2018 was $-5.4 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. NxStage Medical's Earnings per Share (Diluted) for the three months ended in Sep. 2018 was $0.01.


NxStage Medical Net Income Historical Data

The historical data trend for NxStage Medical's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NxStage Medical Net Income Chart

NxStage Medical Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.56 -23.95 -15.34 -4.77 -13.99

NxStage Medical Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.45 -2.27 -1.46 -2.59 0.88

NxStage Medical Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

NxStage Medical's Net Income for the fiscal year that ended in Dec. 2017 is calculated as

Net Income(A: Dec. 2017 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-15.47+0.145+0+1.333
=-14.0

NxStage Medical's Net Income for the quarter that ended in Sep. 2018 is calculated as

Net Income(Q: Sep. 2018 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1.302+-0.512+0+0.091
=0.9

Net Income for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NxStage Medical  (NAS:NXTM) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

NxStage Medical's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2018 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


NxStage Medical Net Income Related Terms

Thank you for viewing the detailed overview of NxStage Medical's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NxStage Medical (NxStage Medical) Business Description

Traded in Other Exchanges
N/A
Address
NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.
Executives
Earl R Lewis director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Craig W Moore director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Jeffrey H Burbank director, officer: Chief Executive Officer NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
James J Peters director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Kevin Hershberger officer: Chief Accounting Officer 350 MERRIMACK STREET, LAWRENCE MA 01843
Philippe O. Chambon director C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NxStage Medical (NxStage Medical) Headlines

From GuruFocus

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares

By GuruFocus Research GuruFocus Editor 03-18-2011

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,000 Shares

By GuruFocus Research GuruFocus Editor 07-15-2010

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares

By GuruFocus Research GuruFocus Editor 12-17-2010

Medisystems Announces US Release of MasterGuard® Plus

By PRNewswire PRNewswire 04-13-2018

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,000 Shares

By GuruFocus Research GuruFocus Editor 08-19-2010

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares

By GuruFocus Research GuruFocus Editor 02-18-2011

NxStage Celebrates Fifth Annual National Home Hemodialysis Day

By PRNewswire PRNewswire 03-15-2018